Literature DB >> 15000337

Ankylosing spondylitis. Not just another pain in the back.

Walter P Maksymowych1.   

Abstract

OBJECTIVE: To review recent developments in diagnosis and treatment of ankylosing spondylitis (AS). QUALITY OF EVIDENCE: Level I evidence from three randomized placebo-controlled trials shows that AS is highly responsive to anti-tumour necrosis factor-alpha (anti-TNFalpha) therapies when the standard approach of nonsteroidal anti-inflammatory drugs (NSAIDs) and physical modalities fails. MAIN MESSAGE: Ankylosing spondylitis is associated with disability comparable to that of rheumatoid arthritis. Diagnosis should first focus on eliciting a history of nocturnal back pain, diurnal variation in symptoms with prolonged morning stiffness, and a good response to NSAID therapy. Physical examination is often unrevealing. Pelvic x-ray results are often normal in early disease. Magnetic resonance imaging is the most sensitive imaging technique for detecting early inflammatory lesions and should be considered when history supports the diagnosis but results of plain radiography are normal. When patients have failed at least two courses of NSAID therapy, anti-TNF(alpha)therapies are of proven benefit.
CONCLUSION: New magnetic resonance imaging techniques and highly effective therapies make AS more readily detectable and managable.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15000337      PMCID: PMC2214553     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  21 in total

1.  Functional disability predicts total costs in patients with ankylosing spondylitis.

Authors:  Michael M Ward
Journal:  Arthritis Rheum       Date:  2002-01

2.  Clinical history as a screening test for ankylosing spondylitis.

Authors:  A Calin; J Porta; J F Fries; D J Schurman
Journal:  JAMA       Date:  1977-06-13       Impact factor: 56.272

3.  Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers.

Authors:  A Zink; J Braun; J Listing; J Wollenhaupt
Journal:  J Rheumatol       Date:  2000-03       Impact factor: 4.666

4.  Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.

Authors:  Jennifer D Gorman; Kenneth E Sack; John C Davis
Journal:  N Engl J Med       Date:  2002-05-02       Impact factor: 91.245

5.  Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug.

Authors:  M Dougados; J M Béhier; I Jolchine; A Calin; D van der Heijde; I Olivieri; H Zeidler; H Herman
Journal:  Arthritis Rheum       Date:  2001-01

Review 6.  Scientific contributions of ankylosing spondylitis patient advocacy groups.

Authors:  E Feldtkeller; J Bruckel; M A Khan
Journal:  Curr Opin Rheumatol       Date:  2000-07       Impact factor: 5.006

7.  Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.

Authors:  J Braun; J Brandt; J Listing; A Zink; R Alten; W Golder; E Gromnica-Ihle; H Kellner; A Krause; M Schneider; H Sörensen; H Zeidler; W Thriene; J Sieper
Journal:  Lancet       Date:  2002-04-06       Impact factor: 79.321

8.  Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy.

Authors:  Filip Van Den Bosch; Elli Kruithof; Dominique Baeten; Annemie Herssens; Filip de Keyser; Herman Mielants; Eric M Veys
Journal:  Arthritis Rheum       Date:  2002-03

Review 9.  Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis.

Authors:  Walter P Maksymowych; Robert D Inman; Dafna Gladman; Glen Thomson; Millicent Stone; Jacob Karsh; Anthony S Russell
Journal:  J Rheumatol       Date:  2003-06       Impact factor: 4.666

Review 10.  Novel therapies in the treatment of spondyloarthritis.

Authors:  Walter P Maksymowych
Journal:  Expert Opin Investig Drugs       Date:  2002-07       Impact factor: 6.206

View more
  4 in total

1.  Characteristics and medical management of patients with rheumatoid arthritis and ankylosing spondylitis.

Authors:  H Bodur; S Ataman; L Akbulut; D Evcik; V Kavuncu; T Kaya; R Günaydin; B Kuran; N Kotevoğlu; A Bal; E Aydoğ; Z Altay; H Uğurlu; H Kocabaş; N Olmez; P Yazgan; S Gürsoy; E Madenci; S Ozel; S U Delialioğlu
Journal:  Clin Rheumatol       Date:  2008-03-21       Impact factor: 2.980

2.  25 Years Old Women With Inflammatory Low Back Pain.

Authors:  Zahra Soltani; Fereydon Davatchi
Journal:  Med Arch       Date:  2016-05-31

3.  We Got Your Back! Help Care Seeking and Caregiving in Mexican Indigenous Men With Ankylosing Spondylitis.

Authors:  Joan Francisco Matamoros-Sanin; Juan Guillermo Figueroa-Perea; César Pacheco-Tena; Ingris Peláez-Ballestas
Journal:  Am J Mens Health       Date:  2019 Jul-Aug

4.  Expression and function of Toll‑like receptors in peripheral blood mononuclear cells in patients with ankylosing spondylitis.

Authors:  Jun Zhang; Rongming Xu; Lei Wu; Jihong Jiang
Journal:  Mol Med Rep       Date:  2019-09-02       Impact factor: 2.952

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.